Icotinib, as a first-generation EGFR-TKI developed in China, demonstrated similar results as gefitinib and erlotinib in patients with EGFR-sensitive mutations, which has been approved by the National Medical Products Administration (NMPA) in 2011 for the treatment of patients with advanced EGFR-sensitive mutation NSCLC (Shi et al., 2013). Here, EGFR is linked to non-small cell lung carcinoma.